1-4 of 4
Saad Z. Usmani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets

Urvi A. Shah, Kylee H. Maclachlan, Andriy Derkach, Meghan Salcedo, Kelly Barnett, Julia Caple, Jenna Blaslov, Linh Tran, Amanda Ciardiello, Miranda Burge, Tala Shekarkhand, Peter Adintori, Justin Cross, Matthew J. Pianko, Kinga Hosszu, Devin McAvoy, Sham Mailankody, Neha Korde, Malin Hultcrantz, Hani Hassoun, Carlyn R. Tan, Sydney X. Lu, Dhwani Patel, Benjamin Diamond, Gunjan Shah, Michael Scordo, Oscar Lahoud, David J. Chung, Heather Landau, Saad Z. Usmani, Sergio Giralt, Ying Taur, C. Ola Landgren, Gladys Block, Torin Block, Jonathan U. Peled, Marcel R.M. van den Brink, Alexander M. Lesokhin
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (23): 5149–5155.
https://doi.org/10.1158/1078-0432.CCR-22-0723
Published: 01 December 2022
View article titled, Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Open the PDF for Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets in another window
Includes: Supplementary data
Journal Articles

Molecular Chaperone gp96 Is a Novel Therapeutic Target of Multiple Myeloma

Yunpeng Hua, Shai White-Gilbertson, Joshua Kellner, Saleh Rachidi, Saad Z. Usmani, Gabriela Chiosis, Ronald DePinho, Zihai Li, Bei Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (22): 6242–6251.
https://doi.org/10.1158/1078-0432.CCR-13-2083
Published: 14 November 2013
View article titled, Molecular Chaperone gp96 Is a Novel Therapeutic Target of Multiple Myeloma
Open the PDF for Molecular Chaperone gp96 Is a Novel Therapeutic Target of Multiple Myeloma in another window
Journal Articles

A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

Razelle Kurzrock, Peter M. Voorhees, Corey Casper, Richard R. Furman, Luis Fayad, Sagar Lonial, Hossein Borghaei, Sundar Jagannath, Lubomir Sokol, Saad Z. Usmani, Helgi van de Velde, Xiang Qin, Thomas A. Puchalski, Brett Hall, Manjula Reddy, Ming Qi, Frits van Rhee
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3659–3670.
https://doi.org/10.1158/1078-0432.CCR-12-3349
Published: 30 June 2013
View article titled, A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
Open the PDF for A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease in another window
Includes: Supplementary data
Journal Articles

Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Christoph J. Heuck, Jackie Szymonifka, Emily Hansen, John D. Shaughnessy, Jr, Saad Z. Usmani, Frits van Rhee, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty, Clyde Bailey, Joshua Epstein, Antje Hoering, John Crowley, Bart Barlogie
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5499–5506.
https://doi.org/10.1158/1078-0432.CCR-12-0019
Published: 30 September 2012
View article titled, Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <em>NR3C1</em>
Open the PDF for Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <em>NR3C1</em> in another window
Includes: Supplementary data